Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Postmenopausal Women With ER+ HER2- Primary Breast Cancer
Interventions: DRUG: Standard Arm - Fulvestrant|DRUG: AZD9496
Sponsor: AstraZeneca